The New Treatment Dimension

Advancing Glycan Mediated Therapy

GlycoEra AG is advancing glycoengineered therapeutics to address unmet medical needs. Despite significant advancements in understanding the role of glycans in human health and diseases, this knowledge has not translated well into therapeutic drug development, a consequence of the limitations and complexities of controlling glycosylation processes. GlycoEra’s platform has overcome these challenges! The CustomGlycan Platform enables glycan-mediated modes of action through the engineering of highly defined specific glycan structures, accessing a novel combinatorial dimension for the treatment of very challenging diseases.

Get in touch with us if you would like to be part of this amazing new era in therapeutic drug development!

Latest News

  • January 5, 2021

    GlycoEra AG announces its incorporation with the purpose of leveraging a proprietary glycoengineering platform to develop a pipeline of novel biologics for inflammatory disease, autoimmune disorder and immuno-oncology indications. View press release

  • December 24, 2020

    GlycoEra is attending the J.P. Morgan 39th Annual Healthcare Conference (Jan 11-14, 2021)

  • December 23, 2020

    GlycoEra is presenting at Biotec Showcase (Jan 11-15, 2021)

View more news